Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS.
暂无分享,去创建一个
[1] L. Scheinberg,et al. Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion. , 1981, Laboratory investigation; a journal of technical methods and pathology.
[2] J. Cossins,et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions , 1997, Acta Neuropathologica.
[3] P. Dore‐Duffy,et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central neurvous system microvessels from patients with multiple sclerosis , 1994, Annals of neurology.
[4] W. Mcdonald,et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.
[5] Hans Lassmann,et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions , 1995, Annals of neurology.
[6] J. Benjamins,et al. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[7] Remyelination in multiple sclerosis , 1979, Annals of neurology.
[8] H. Lassmann,et al. Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna , 1998, Journal of Neuroimmunology.
[9] W. Brück,et al. Oligodendrocytes in the early course of multiple sclerosis , 1994, Annals of neurology.
[10] U. Traugott. Multiple sclerosis: relevance of Class I and Class II MHC-expressing cells to lesion development , 1987, Journal of Neuroimmunology.
[11] R. Sobel,et al. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. , 1990, The American journal of pathology.
[12] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[13] F. Barkhof,et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.
[14] V. Perry,et al. Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.
[15] Jack Antel,et al. Phenotypic Differences between Human Monocytes/Macrophages and Microglial Cells Studied In Situ and In Vitro , 1994, Journal of neuropathology and experimental neurology.
[16] C. Brosnan,et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.
[17] A. Olivier,et al. Fc Receptors for IgG on Cultured Human Microglia Mediate Cytotoxicity and Phagocytosis of Antibody-coated Targets , 1994, Journal of neuropathology and experimental neurology.
[18] A. Compston. The 150th anniversary of the first depiction of the lesions of multiple sclerosis. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[19] P. Sminia,et al. Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. , 1999, Journal of neuropathology and experimental neurology.
[20] K. Jellinger,et al. Patterns of oligodendroglia pathology in multiple sclerosis. , 1994, Brain : a journal of neurology.
[21] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[22] R. Weller. A Colour Atlas of Multiple Sclerosis and Other Myelin Disorders , 1989 .
[23] Moses Rodriguez,et al. Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.
[24] J. Newcombe,et al. Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions , 1998, Journal of Neuroimmunology.
[25] C. Raine,et al. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions , 1976, Neurology.
[26] G. D. De Meyer,et al. RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. , 1998, The American journal of pathology.
[27] C. Raine,et al. Multiple sclerosis: Oligodendrocytes display cell death–related molecules in situ but do not undergo apoptosis , 1997, Annals of neurology.
[28] M. Cuzner,et al. Microglia Express MHC Class II in Normal and Demyelinating Human White Matter , 1988, Annals of the New York Academy of Sciences.
[29] C. Brosnan,et al. Cytokine localization in multiple sclerosis lesions , 1995, Neurology.
[30] B. Trapp,et al. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions , 1994, Journal of Neuroimmunology.
[31] R. Sobel,et al. Fibronectin in multiple sclerosis lesions. , 1989, The American journal of pathology.
[32] Hans Lassmann,et al. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.
[33] M. Goebeler,et al. The calcium‐binding proteins MRP8 and MRP14 form a membrane‐associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions , 1992, European journal of immunology.
[34] F. Barkhof,et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.
[35] C. Raine,et al. The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.
[36] C. Lumsden. Fundamental Problems in the Pathology of Multiple Sclerosis and Allied Demyelinating Diseases* , 1951, British medical journal.